# Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

> **NCT02082522** · PHASE3 · TERMINATED · sponsor: **Concordia Laboratories Inc.** · enrollment: 28 (actual)

## Conditions studied

- Hilar Cholangiocarcinoma

## Interventions

- **DRUG:** Photodynamic therapy-Photofrin
- **PROCEDURE:** Stenting procedure
- **DRUG:** Chemotherapy regimen

## Key facts

- **NCT ID:** NCT02082522
- **Lead sponsor:** Concordia Laboratories Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-12
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-01-12
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Accrual rate remaining too low
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082522, "Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02082522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*